Double Blind Test

Type: Keyphrase
Name: Double Blind Test
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

Summit receives US green light for phase II studies on C.diff drug

Drug developer Summit () has been given the go ahead by American regulators to begin its phase-two, proof-of-concept study on a new-generation antibiotic for C. difficile infection (CDI).The Food & Drug Administration clearance paves the way for trials ... [Published Proactive - Mar 18 2014]


Chief executive Glyn Edwards added: "If this profile is replicated in future studies, SMT19969 could potentially offer a differentiated and more beneficial option to current CDI treatments, which continue to undermine the natural balance of the gut flora and lead to recurrent disease."

More Content

All (1) | News (1) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Summit receives US green light for phase II stu... [Published Proactive - Mar 18 2014]
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.